Tilray Brands Inc is a global leader in the cannabis industry, specializing in the cultivation, production, and distribution of a diverse range of cannabis products. The company operates across various segments, including medical and recreational cannabis, as well as hemp-derived wellness products. Tilray focuses on innovation and quality, offering a portfolio that encompasses various formats such as dried flower, oils, edibles, and beverages. In addition to its core cannabis business, Tilray is dedicated to advancing research, education, and consumer awareness within the rapidly evolving market, positioning itself as a key player in the development and expansion of cannabis-related offerings worldwide. Read More
Tilray’s third quarter results were met with a strong positive response from the market, reflecting the company's progress in expanding its diversified business model and achieving a notable improvement in operating margin. Management attributed the quarter’s performance to double-digit growth in Canadian adult-use and international cannabis segments, as well as operational improvements across its beverage and wellness divisions. CEO Irwin Simon highlighted that, outside of a flat beverage segment affected by SKU rationalization, all core business lines contributed to revenue growth, with focused efforts on product innovation and efficiency driving the company’s improved profitability.
A Marijuana Moment report cites findings from a new study showing medical cannabis legalization leads to significant reductions in opioid prescriptions.
Target is testing the sale of THC-infused drinks at a small number of stores in Minnesota, according to executives from cannabis drink companies involved in the rollout.
Target is testing the sale of THC-infused drinks at a small number of stores in Minnesota, according to executives from cannabis drink companies involved in the rollout.
NEW YORK, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Tilray Medical (“Tilray”), a division of Tilray Brands, Inc. (NASDAQ: TLRY and TSX: TLRY) and a global leader in medicinal cannabis, empowering the therapeutic alliance between patients and healthcare practitioners to make informed individualized health decisions, transforming healthcare, has announced plans to expand its medical cannabis operations into Panama. In connection with its expansion into Panama, Tilray has entered into a joint venture with Top Tech Global Inc. (“Top Tech”), whose members have extensive experience in the distribution of medical devices since 2014. Together, Tilray and Top Tech, through their joint venture company, Solana Life Group, have received a medical cannabis license issued by the National Directorate of Pharmacy and Drugs in Panama authorizing the cultivation, manufacturing, import, export, distribution and sale of medical cannabis in Panama.
Companies that burn cash at a rapid pace can run into serious trouble if they fail to secure funding.
Without a clear path to profitability, these businesses risk dilution, mounting debt, or even bankruptcy.
Curious about the most active stocks in today's session? Get a glimpse into the stocks that are generating the highest trading volume and capturing market attention.
Cannabis company Tilray Brands (NASDAQ:TLRY) beat Wall Street’s revenue expectations in Q3 CY2025, with sales up 4.7% year on year to $209.5 million. Its non-GAAP loss of $0 per share increased from -$0.04 in the same quarter last year.
Health In Tech Inc. (Nasdaq: HIT), a rapidly advancing Insurtech company leveraging AI and blockchain to modernize healthcare administration, is showcasing its enhanced Do It Yourself Benefit System (eDIYBS) at the upcoming SIIA National Conference , October 12–14, 2025, in Phoenix, Arizona. The announcement follows the company’s recent strategic Letter of Intent (LOI) with AlphaTON Capital Corp. (Nasdaq: ATON) to co-develop HITChain , a blockchain-powered healthcare insurance claims platform built on The Open Network (TON) .
Shares of cannabis company Tilray Brands (NASDAQ:TLRY)
jumped 24.9% in the morning session after the company reported third-quarter financial results that topped analyst expectations.
